Albireo Pharma IncのBeta
Albireo Pharma IncのBetaは何ですか。
Albireo Pharma IncのBetaは0.00です。
Betaの定義は何ですか。
BETAは、株式が市場全体よりも多かれ少なかれ揮発性であるかどうかを示します。 1未満のベータは株式が市場よりも揮発性が低いことを示し、1より大きいベータは株式がより揮発性であることを示します。ボラティリティは、平均値周辺の価格の変動として測定されます。
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
NASDAQのセクタHealth CareにおけるBetaの企業と比べるAlbireo Pharma Inc
Albireo Pharma Incは何をしますか。
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Incと類似のbeta
- Vision Marine TechnologiesのBetaは0.00です。
- Ely Gold RoyaltiesのBetaは0.00です。
- Glacier Lake ResourcesのBetaは0.00です。
- Magnum Mining and ExplorationのBetaは0.00です。
- Africa Opportunity FundのBetaは0.00です。
- Fulcrum Utility ServicesのBetaは0.00です。
- Albireo Pharma IncのBetaは0.00です。
- GullewaのBetaは0.00です。
- S.A.L. SteelのBetaは0.00です。
- Andina Acquisition IIIのBetaは0.00です。
- Andina Acquisition IIIのBetaは0.00です。
- Brilliant AcquisitionのBetaは0.00です。
- IndokemのBetaは0.00です。